Endothelium-Derived Nitric Oxide Regulates Arterial Elasticity in Human Arteries In Vivo

DOI Web Site 被引用文献14件
  • Scott Kinlay
    From the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass.
  • Mark A. Creager
    From the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass.
  • Mariko Fukumoto
    From the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass.
  • Hiroyuki Hikita
    From the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass.
  • James C. Fang
    From the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass.
  • Andrew P. Selwyn
    From the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass.
  • Peter Ganz
    From the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass.

抄録

<jats:p> Arterial elasticity is determined by structural characteristics of the artery wall and by vascular smooth muscle tone. The identity of endogenous vasoactive substances that regulate elasticity has not been defined in humans. We hypothesized that NO, a vasodilator released constitutively by the endothelium, augments arterial elasticity. Seven healthy young men were studied. A 20-MHz intravascular ultrasound catheter was introduced through an arterial sheath to measure brachial artery cross-sectional area, wall thickness, and intra-arterial pressure. After control was established, indices of elasticity (pressure-area relationship, instantaneous compliance, and stress-strain, pressure–incremental elastic modulus (E <jats:sub>inc</jats:sub> ), and pressure–pulse wave velocity relationships) were examined over 0 to 100 mm Hg transmural pressure obtained by inflation of an external cuff. Thereafter, the basal production of endothelium-derived NO was inhibited by <jats:italic>N</jats:italic> <jats:sup>G</jats:sup> -monomethyl- <jats:sc>l</jats:sc> -arginine (L-NMMA) (4 and 8 mg/min). Finally, nitroglycerin (2.5 and 12.5 μg/min), an exogenous donor of NO, was given to relax the vascular smooth muscle. Elasticity was measured under all of these conditions. L-NMMA (8 mg/min) decreased brachial artery area ( <jats:italic>P</jats:italic> =0.016) and compliance ( <jats:italic>P</jats:italic> <0.0001) and increased E <jats:sub>inc</jats:sub> ( <jats:italic>P</jats:italic> <0.01) and pulse wave velocity ( <jats:italic>P</jats:italic> <0.0001). Nitroglycerin (12.5 μg/min) increased brachial artery area ( <jats:italic>P</jats:italic> <0.001) and compliance ( <jats:italic>P</jats:italic> <0.001) and decreased pulse wave velocity ( <jats:italic>P</jats:italic> =0.02). NO, an endothelium-derived vasodilator, augments arterial elasticity in the human brachial artery. Loss of constitutively released NO associated with cardiovascular risk factors may adversely affect arterial elasticity in humans. </jats:p>

収録刊行物

  • Hypertension

    Hypertension 38 (5), 1049-1053, 2001-11

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (14)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ